UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, exercised 9,500 stock options and sold the resulting 9,500 common shares via a 10b5-1 plan for roughly $5 million in total proceeds while retaining significant indirect holdings.

On July 23, 2026, United Therapeutics Corporation Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at an exercise price of $135.42 per share and acquired an equal number of common shares, then sold those 9,500 shares in a series of open-market transactions at prices ranging from approximately $522.87 to $531.83 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The gross proceeds from the sales totaled roughly $5.0 million versus an exercise cost of about $1.3 million, implying an approximate spread of $3.7 million. After these transactions, the trust’s indirect ownership stood at 324,443 shares in the main reported block, with additional indirect holdings across several family trusts and through a spouse, plus 284,410 shares underlying options held by a family trust, reflecting continued substantial exposure to United Therapeutics equity despite the programmed sale.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000105

Alert Tier

6